Bristol-Myers Squibb Co

Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.

Johnson & Johnson has submitted an application to European regulators to expand the use of its myeloma drug Tecvayli as a monotherapy after just one prior treatment. This follows recent U.S. approval for a Tecvayli combination and is supported by trial data showing a 71% reduction in disease progression risk.

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.

Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.